Novartis announces results of clinical study PIONEER-HF for heart failure drug Entresto milestone

recently, SwissPharmaceuticalsannounced the results of a landmark clinical study of PIONEER-HF for heart failuredrug(sacubitril/valsartan)aboutEntresto is a dual-acting angiotensin receptor-brainmorphine inhibitor (ARNI) with a unique role model that enhances the heart's protective neuroendocrine system (NP system, sodium urethra system) while inhibiting harmful systems (RAAS system, renin-angiotensin-aldosterone system) that is thought to reduce the strain of heart failureEntresto combines Novartis hypertension drug Davin (general name: valsartan, sacubitin) and sacubitril, a morphine peptide inhibitor that blocks the action mechanism of two peptides that threaten lower blood pressure, and valsartan is an antagonist type of antagonist II receptor antagonists that improve semaphore and stimulate the body's sodiumrelated studies
PIONEER-HF is a forward-looking, multicenter, double-blind, randomized, controlled clinical study designed to reduce the safety, tolerance and effectiveness of Entresto treatment during hospitalization compared to clinically commonly used heart failure drug elapur (enalbul) in patients who were admitted to hospital for acute indemnifying heart failure (ADHF) events and with stable blood-scapability scoresstudy included a total of 881 patients aged 18 and over, with an average age of 61 years, a blood-shot score (EF) of 40%, and an increase in the level of the precursor of the amino end B-sodium peptide (NT-ProBNP s 1600pg) /mL or b-type sodium urethra peptides (BNP) of 400pg/mL, does not round its diagnosis time and the duration of treatment of angiotensin-converting enzyme inhibitors (ACEi) and/or angiotensin receptor blockers (ARB)instudies, admitted patients were randomly assigned to receive Entresto or Irapri treatment twice a day after their condition was stableThe main endpoint was the change in the average time ratio of NT-proBNP relative to baseline in weeks 4 and 8 of treatmentdata showed that the study reached its main endpoint, with the average NT-proBNP level of Entresto treatment dropping by 47% relative to the baseline and the 25% decrease in the Enapuri treatment group, which translates into a statistically significant 29% reduction in Entresto compared to Inapri (95% CI: 0.63-0.81, p 0.0001)In addition, a significant decrease in NT-proBNP was observed in the Entresto treatment group within one week of initiating treatment, Entresto's advantages in reducing NT-proBNP were consistent among different HFrEF patients who were stable after ADHF admission, including those newly diagnosed WithFrEF patients, patients not treated with ACEi/ARB, and African-Americans